Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 0:05 |
Speaker Introduction and Agenda |
Rachel Rabinovitch, MD, FASTRO
Radiation Oncologist, Professor, Radiation Oncology, University of Colorado
| 1:08 |
Background DCIS Treatment – Radiation Therapy Landmark Trials |
Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 10:35 |
Data Overview and Clinical Evidence |
| 11:20 |
DCISionRT Test Report |
| 12:39 |
Integration of Biology and Clinicopathologic Factors |
| 16:50 |
DCISionRT Demonstrates Consistent RT Prediction |
| 18:20 |
DCISionRT Correctly Reclassifies ClinPath in All Validation Cohorts |
| 22:46 |
Supportive Evidence DCISionRT |
Rachel Rabinovitch, MD, FASTRO
Radiation Oncologist, Professor, Radiation Oncology, University of Colorado
| 24:15 |
Clinical Application in Radiation Oncology – My Approach to DCIS |
Panel Q and A Discussion
| 38:47 |
Q&A and Discussion |
| 38:58 |
Test’s impact on mastectomy decisions |
| 40:40 |
Risk assessment by ClinPath |
| 42:05 |
Integrating into tumor board and workflow |
| 42:58 |
Test’s impact on boost decisions |
| 44:55 |
Test’s impact on margins assessment |
| 51:19 |
DCISionRT vs OncotypeDCIS |
| 52:40 |
ex-US availability |
| 53:06 |
Getting started and specimen requirements |
| 56:55 |
Test’s impact regarding endocrine therapy |
